8-KOther Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report (Aug 1, 2001)

Filed August 1, 2001For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) has announced the completion of its acquisition of Aurora Biosciences Corporation, effective July 18, 2001. This strategic move, structured as a tax-free stock-for-stock merger, involved issuing approximately 14.1 million shares of Vertex common stock and cash for fractional shares to Aurora stockholders. The acquisition is being accounted for using the pooling of interests method, signifying a combination of entities rather than a purchase. Aurora Biosciences, a company focused on technologies to accelerate drug discovery for the pharmaceutical and biopharmaceutical industries, will operate as a wholly-owned subsidiary of Vertex. This integration is expected to enhance Vertex's capabilities in drug discovery. The merger also led to adjustments in Aurora's outstanding stock options, which were converted into options to purchase Vertex stock with adjusted exercise prices and quantities. Dr. Stuart J.M. Collinson, Aurora's former CEO, has joined Vertex's Board of Directors.

Key Highlights

  • 1Vertex Pharmaceuticals completed the acquisition of Aurora Biosciences Corporation on July 18, 2001.
  • 2The acquisition was executed as a tax-free stock-for-stock merger, with Vertex issuing approximately 14.1 million shares.
  • 3The transaction will be accounted for as a 'pooling of interests' business combination.
  • 4Aurora Biosciences will continue its operations as a wholly-owned subsidiary of Vertex.
  • 5Aurora's expertise in drug discovery technologies is expected to bolster Vertex's research and development efforts.
  • 6Aurora's outstanding stock options were converted into Vertex stock options with adjusted terms.
  • 7Dr. Stuart J.M. Collinson, former CEO of Aurora, has joined Vertex's Board of Directors.

Frequently Asked Questions

The primary impact is the announcement of Vertex's completed acquisition of Aurora Biosciences. This signifies a significant expansion of Vertex's capabilities, particularly in drug discovery technologies, and involves the issuance of new Vertex shares to Aurora's former shareholders.

The acquisition was structured as a merger of a Vertex subsidiary with Aurora Biosciences. It was a tax-free stock-for-stock exchange, meaning Aurora shareholders received Vertex common stock. The transaction will be accounted for as a 'pooling of interests' business combination, which combines the balance sheets of both companies as if they had always been merged.

Aurora Biosciences will continue its operations as a wholly-owned subsidiary of Vertex Pharmaceuticals and will retain its name. This suggests an integration aimed at leveraging Aurora's drug discovery expertise within the larger Vertex organization.

Vertex assumed Aurora's outstanding stock options. These options were converted into options to purchase Vertex common stock. The number of shares issuable upon exercise was adjusted by multiplying by 0.62, and the per-share exercise price was adjusted by dividing by 0.62, with specific rounding rules applied.